Correction to: Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells (Oncogene, (2017), 36, 11, (1487-1502), 10.1038/onc.2016.310);Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells

Oncogene

Volumn 36, Issue 11, 2017, Pages 1487-1502

  Safferthal, C ^a   Rohde, K ^a   Fulda, S ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BV 6; CASPASE 8; CD34 ANTIGEN; CELL PROTEIN; ETANERCEPT; INHIBITOR OF APOPTOSIS PROTEIN; PEPTIDOMIMETIC AGENT; PROTEIN MLKL; PROTEIN RIP1; PROTEIN RIP3; SMAC MIMETIC; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; UNCLASSIFIED DRUG; BV6 PEPTIDE; CASPASE; DNM1L PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PROTEIN; MLKL PROTEIN, HUMAN; OLIGOPEPTIDE; PGAM5 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR 1;

ACUTE MYELOID LEUKEMIA; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BLAST CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG TARGETING; HUMAN; HUMAN CELL; MYELOID LEUKEMIA CELL LINE; NECROPTOSIS; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NECROSIS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; GTP PHOSPHOHYDROLASES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL PROTEINS; NECROSIS; OLIGOPEPTIDES; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN KINASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84996743387     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-024-03022-3     Document Type: Erratum

References (39)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907.
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
3. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-241.
4. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
5. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367.
6. Fulda S, Vucic D, Targeting IAP. proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-124.
7. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
8. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004; 5: 489-495.
9. Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol 2007; 25: 1209-1215.
10. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110: 1291-1300.
11. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681.
12. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
13. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
14. Chromik J, Safferthal C, Serve H, Fulda S. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 2014; 344: 101-109.
15. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013; 4: e802.
16. Steinwascher S, Nugues AL, Schoeneberger H, Fulda S. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. Cancer Lett 2015; 366: 32-43.
17. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3- expressing cells. Mol Cancer Ther 2007; 6: 1951-1961.
18. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24: 2100-2109.
19. Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-Stella C et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs 2011; 29: 1264-1275.
20. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst 2014; 106: djt440.
21. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S et al. Smac Mimetic Bypasses Apoptosis Resistance in FADD- or Caspase-8- Deficient Cells by Priming for Tumor Necrosis Factor alpha-Induced Necroptosis. Neoplasia 2011; 13: 971-979.
22. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
23. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylationdriven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
24. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
25. Fulda S. Promises and challenges of Smac mimetics as cancer therapeutics. Clin Cancer Res 2015; 21: 5030-5036.
26. Wang Z, Jiang H, Chen S, Du F, Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 2012; 148: 228-243.
27. Schenk B, Fulda S. Reactive oxygen species regulate Smac mimetic/TNFalphainduced necroptotic signaling and cell death. Oncogene 2015; 34: 5796-5806.
28. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimeticinduced apoptosis. Cancer Cell 2007; 12: 445-456.
29. Volk A, Li J, Xin J, You D, Zhang J, Liu X et al. Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing human AML. J Exp Med 2014; 211: 1093-1108.
30. Fulda S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia 2012; 26: 1155-1165.
31. Moriwaki K, Farias Luz N, Balaji S, De Rosa MJ, O'Donnell CL, Gough PJ et al. The Mitochondrial Phosphatase PGAM5 Is Dispensable for Necroptosis but Promotes Inflammasome Activation in Macrophages. J Immunol 2016; 196: 407-415.
32. Chu WM. Tumor necrosis factor. Cancer Lett 2013; 328: 222-225.
33. Lalaoui N, Hanggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L et al. Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. Cancer Cell 2016; 29: 145-158.
34. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
35. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014; 32: 3103-3110.
36. Belz K, Schoeneberger H, Wehner S, Weigert A, Bonig H, Klingebiel T et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014; 124: 240-250.
37. DiPersio J, Erba H, Larson R, Luger S, Mangan K, Tallman M et al. Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). J Clin Oncols 2014; 32(15 suppl): 7029.
38. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95: 301-308.
39. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009; 113: 1710-1722.